EuropaBio’s State of European Biotech Address

Review of year past & future outlook | 2014–2015

The European Association for BioindustriesThe European Association for Bioindustries

2

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

3

Re

view

of ye

ar past &

futu

re o

utlo

ok

EuropaBio at a Glance 5

The State of European Biotech Address 6

Talking Benefits: Biotech for Life 8

The State of Healthcare Biotech in Europe 10

The State of Agricultural Biotech in Europe 14

The State of Industrial Biotech in Europe 18

EuropaBio Team 22

EuropaBio Members 24

4

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

5

Re

view

of ye

ar past &

futu

re o

utlo

ok

EuropaBio at a Glance

We are EuropaBio, the European Association for Bioindustries, created in 1996 to promote an innovative and dynamic biotechnology-based industry in Europe.

We are committed to the socially responsible use of biotech-nology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to replace oil-based products and pro-cesses with biobased products and processes. Our members adhere to common core ethical values that guide our work.

Our membership is composed of 60 corporate members, 13 associate members and bio regions, and 17 national bio-technology associations representing over 1800 European biotech SMEs.

EuropaBio has a Management Board made up of represen-tatives of member companies and national associations. The Board is supported by the secretariat staff members who carry out day to day activities under the management of the Secretary General. The three main sectors of biotechnology are represented through Councils: Healthcare (Red Biotech), Industrial (White Biotech) and Agri-Food (Green Biotech). Through our National Associations Council and horizontal SME Platform, we represent more than 1800 biotech small and medium-sized enterprises across Europe.

In an independent survey by APCO and EurActiv in 2013, EuropaBio was ranked as the most effective trade association in Brussels.

in BRUSSELS Trade Association

2 0 1 3

in BRUSSSELS

6

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Footnotes:

1 ‘2014: A new benchmark year for biotech IPOs’, EY Changing Business of

Life Sciences Blog, January 9, 20152 ‘The IPO wave continues’, European

Biotechnology Magazine, Spring Edition, Vol. 14, 2015, p. 24

3 Idem4 European Biotech Stock Market

Monitor, BIOCOM AG5 ‘UK life sciences hit 7-year high’, Financial Times, October 6, 2014

6 ‘Biotechnology in Europe: The Tax, Finance and Regulatory Framework

and Global Policy Comparison’, EY and EuropaBio joint report, page 7. The

report can be downloaded on www.europabio.org.

Nathalie Moll

Carlo Incerti

7

Re

view

of ye

ar past &

futu

re o

utlo

ok

The State of European Biotech Address

By: Carlo Incerti, EuropaBio Chair & Nathalie Moll, EuropaBio Secretary General

Enabling a European industry at full sail to overcome rough seas.

AN INDUSTRY AT FULL SAIL‘Unprecedented. Record-setting. Red-hot.’ At the start of 2015 EY used these words to characterise the US IPO and investment climate during the previous year1. This confidence and optimism seems to have caught on across the Atlantic as well, with 2014 having been an exceptional year in terms of investment in European biotech. The European stock-exchanges saw almost two and a half billion Euros being invested in new bio-tech companies (25% more compared to 2013) and 15 companies going public in 2014 (three times more than in 2013)2. This meant that by the end of the year there were 150 publicly list-ed biotech companies worth 66 billion Euros in Europe, showing an industry at full sail and past the economic setbacks of previous years3. This trend has continued with another seven IPOs in the first quarter of 20154.

A HUB FOR LIFE SCIENCES ACROSS THECHANNELOne of the main actors in the financing upswing has been the UK, which showed its confidence in the industry by appointing a former healthcare entrepreneur, George Freeman, as its first ever Life Sciences Minister. The government’s efforts to promote investment in biotech have contri- buted to making the country the top European destination in terms of life sciences fundraising, with almost one billion Euros capital raised by the middle of 20145.

A QUESTION MARK OVER EUROPEAlthough a number of other individual EU coun-tries have also done exceptionally well in the past 12 months, a similarly strong and coherent po-litical commitment may be more difficult to find at European level, where the risk remains that

the EU ‘becomes the world’s biotech research hub while innovative products and processes and the jobs and growth that go with their de-velopment, will be found elsewhere’6. Other re-gions are highly competitive in terms of attracting biotech companies and ensuring they get their products on the market. One main setback in Europe is a less predictable and in some sec-tors, non-science-based regulatory framework, evidenced most recently by the move away from the Single Market in amending the Direc-tive on cultivation of GMOs in Europe. The EU also needs to do more to ensure the excellent funding and tailored market pull measures of-fered by other parts of the world are available to biotech companies, and that concrete measures are put in place to ensure more equitable access to biotech products and processes for patients, farmers and consumers.

FUTURE IMPERFECT?As we set out in our industry Manifesto a year ago, this European Commission and Parliamenta-ry term will determine the success of Europe’s biotech industry. The term is focused on growth, jobs and investment. No other industry is better placed to realise these goals from within Europe. Europe has the brainpower in its science, the willingness in its biotech companies and entre-preneurs and patients, farmers and consumers waiting for solutions. The question is: will our leaders fix the remaining stumbling blocks and enable biotech to deliver its results in terms of societal solutions, growth and jobs here in Eu-rope, or not? As our industry’s leading association and voice at EU level, we look forward to working with all stakeholders to ensure this opportunity is not missed.

8

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

#Biotech4Life

The whole team at EuropaBio has joined forces to invigorate our social media presence. LinkedIn, Twitter and Facebook are now updated on a daily basis with the latest news on #biotech and with live comments during internal/external events. Check them out and engage with us using #Biotech4Life!

Talking Benefits: Biotech for Life

EuropaBio is showcasing the benefits and value of biotechnology through annual flagship initiatives as well as social media.

The 2014 SME Awards judges, winners (French Erytech Pharma and Italian Bio-on) and finalists (Danish Biosyntia, British Autifony Therapeutics, and Dutch BBB Therapeutics)

On 8 October, EuropaBio opened the Euronext markets in Brussels to mark the presentation of the 5th Most Innovative EU Biotech SME Award. At the end of the ceremony which had a strong focus on access to finance for European biotech small and medium-sized enterprises (SMEs), Antti Peltomäki, Deputy Director General of DG Entre-

5th Most Innovative EU Biotech SME Award

prise & Industry, proudly rewarded two innovative biotech SMEs: Erytech Pharma, a French health-care SME developing cancer therapies, and Bio-on, an Italian industrial SME creating bioplastics, as the most innovative biotech SMEs in Europe in 2014.

Re

view

of ye

ar past &

futu

re o

utlo

ok

More than 100 events and activities took place across Europe during Biotech Week 2014

Following on from the great success in 2013, the 2nd edition of the European Biotech Week took place between 6 – 12 October 2014. With 100+ events and activities in 14 European countries, there was something for anyone with a curious mind and an interest in biotech. Visit www.biotechweek.org and have a look inside the magazine “Unraveling the Potential of Biotechnology” to learn more!

2nd edition of the European Biotech Week

9

Opening of the 2014 European Biotech Week exhibition at the European Parliament

10

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Thanks to the application of modern biotechnol-ogy, progress made over the past decade in the understanding of the molecular processes be-hind diseases have enabled scientists to identify new targets for the development of medicines and make new cutting-edge therapies available to patients. Amongst these, progress in studying rare diseases has often led to medical advances offering unexpected leads for more common diseases. Other examples of new concepts en-abled by the application of biotechnology in-clude improved diagnostic techniques for use in personalised medicine, which have already increased survival rates for certain forms of cancers.

By tackling the underlying cause of disease and not simply relieving the symptoms, the innovative treatments that derive from the application of biotechnology are allowing patients to experi-ence better health outcomes. This in turns allows them to stay healthy and active for longer thus reducing pressure on healthcare services.

Despite the incredible benefits brought about by the application of healthcare biotech, few ever make it to mainstream media where the health-care industry is mainly discussed in terms of the cost of treatments and effects on social security budgets rather than in terms of the benefits it of-fers. What is often forgotten is that many preven-tive biotech therapies and treatments are highly cost-effective. They represent a high social return for the investments made by public authorities in terms of healthcare expenditure, and are often “gate openers” for innovative medical research. A telling example of the latter can be taken from the rare disease space: the insertion of

The State of Healthcare Biotech in Europe

Miriam Gargesi, EuropaBio Director of Healthcare Biotechnology

Facing challenges through innovation and ambition.

a select number of vectors for a rare immune deficiency called Wiskott - Aldrich syndrome were later on tested in other immune disorders and eventually used to treat conditions such as leukaemia and Leber’s congenital amaurosis1. In order to continue to foster such break-throughs, European and national policy makers must tackle remaining challenges to the sustain-ability of the healthcare biotech sector. On the one hand, we see how fundamental workable and stable regulatory frameworks as well as the availability of funding are to the upstream stages of the product life-cycle (i.e. discovery, product development and manufacturing). On the oth-er hand, it is clear that the downstream stages of the product life-cycle (i.e. commercialisation of products, access to patients and continued investment in research) are traditionally more af-fected by market-related factors, such as Health Technology Assessment, distribution and pricing policies. It is important that legislative develop-ments as well as market-related policies are im-plemented in such a way that does not discour-age free market competition and incentives for companies to make high-risk investments in the discovery and production of new treatments.

Given the complex landscape of challenges faced by the healthcare biotech industry, we continue to call for a holistic approach by de-cision-makers at both the EU and national level that integrates health, economic and industrial policies and addresses the whole value chain. Policies addressing the economics of supply and demand, supporting incremental innovations throughout the market life-cycle, accelerating uptake of biologics into general medical practice

11

Re

view

of ye

ar past &

futu

re o

utlo

ok

and attracting inward investment in all phases of the innovation process must be put in place and be coherent and supportive of one another.

Maintaining a high level of ambition is crucial if we want to keep accelerating the translation of science into highly effective biologic medicines destined to respond to unmet medical needs, and if we want to realise our goal of potentially curing, and at least dramatically transforming, the lives of European patients.

Footnotes

1 European Medicines Agency 20th anniversary book, p. 29 – available online at: http://tinyurl.com/n9ljedr

Miriam Gargesi

12

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Achievements

Policy recommendations on “Realising the Potential of Personalised Medicine in Europe”

As discussions around more target-ed healthcare intensify, EuropaBio published its second white paper on personalised medicines. This guide sheds light on the chal-lenges for developing and delive- ring personalised medicines to patients. It also provides detailed policy recommendations and calls for action to our decision makers.

http://tinyurl.com/nmelfxv

“Biosimilars in Europe”

As more biosimilars enter the market, EuropaBio developed a new guide that offers an intro-duction to biosimilar medicines, including their contribution to healthcare systems; their regula-tory approval pathway in Europe; and the EuropaBio policy position about the naming, labelling and terms of use for these types of biologic medicines.

http://tinyurl.com/nvy6hgw

Briefing paper on the EU Clinical Trials Regulation

To assist its members, EuropaBio is-sued a briefing paper on the new EU Regulation on Clinical Trials of April 2014. It clarifies how new provisions of the Regulation im-pact clinical research conducted by healthcare biotech companies and which are especially complex for SMEs.

http://tinyurl.com/qb6scml

Key outcomes and impact on clinical research

Briefing Paper on the EU Clinical Trials Regulation

EuropaBio Guide on Biosimilars in Europe When Science Meets Policy

EuropaBio White Paper

Realising the potential of personalised medicine in Europe

With the new European Commissioners and Members of the European Parliament starting their term in 2014, the Healthcare Biotech Unit of EuropaBio and its members focused on ensuring sufficient information was developed to describe the science and potential behind biologic medi-cines and the very specific hurdles faced by

their producers. The following publications were discussed with stakeholders at European and na-tional level over the past year and are the basis of our ongoing efforts to clarify one of the most promising technologies to treat and hopefully cure patients while addressing the pressing needs of healthcare costs in Member States.

13

Re

view

of ye

ar past &

futu

re o

utlo

ok

1 Realised in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA)

“Valuing Healthcare Biotechnology in Europe: EuropaBio’s perspective” brochure

EuropaBio issued the first ever re-port detailing the value of health- care biotechnology in Europe for patients, the economy and Euro-pean society at large to coincide with the new European Commis-sion and Parliament in mid 2014. The resulting brochure describes the complex life-cycle of biologic medicines and the challenges faced by European industry due to global competition and natio- nal level patient-access hurdles among other issues.

http://tinyurl.com/nusgmw7

“Development Process of Orphan Medicinal Products” and “Our 2020 vision”

2015 marks the 15 years anniver-sary of the entry into force of the European Regulation on Orphan Medicinal Products, one of the most successful pieces of legisla-tion. To reflect on this, EuropaBio issued two papers taking stock of the remaining challenges in the development of therapies for rare conditions and outlining the conditions needed for industry to continue to innovate in Europe.1

http://tinyurl.com/p5k67fghttp://tinyurl.com/pqmczl2

Survey on the current state of regulatory and health technology assessment advice to SMEs, in collaboration with the Deerfield Institute

As representatives of thousands of biotech SMEs in Europe, it is important for EuropaBio to fully grasp the issues these companies face in bringing products to the market, such as tackling Health Technology Assessments. The find-ings of a survey run by EuropaBio suggest early regulatory scientific and HTA advice may help SMEs to better prepare and manage their clinical programs toward facilitat-ing both regulatory approval and positive HTA recommendations, and therefore contribute to their increased competitiveness.

http://tinyurl.com/qc2jm94

1

Developmentprocess of

OrphanMedicinalProductsValuing Healthcare

Biotechnology in Europe:

EuropaBio’s perspective

Deerfield Institute - EuropaBio Report on

REGULATORY AND HTA SCIENTIFIC ADVICE

FOR SMALL AND MEDIUM ENTERPRISES

March 2015

EuropaBio-EFPIAJoint Task Forceon Rare Diseasesand Orphan Medicinal Products

Ourvision

2020

14

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

SACRIFICING THE INTERNAL MARKET FOR AGRICULTURAL IMPORTSAs one of its priorities, the EU Commission has recently proposed to give Member States a li-cense to ban the use of GMOs that are approved for import into the EU. This would end the EU internal market and lead to a “Europe à la carte”. The system, which is currently strict but practica-ble on paper, became dysfunctional in practice, as approvals of safe products were put on hold for 18 months before April 2015. The logical way to fix it would be simply by authorising safe prod-ucts and implementing the current legislation, as is common place on an almost daily basis for the many other categories of regulated products.

WHY EUROPE NEEDS GMO APPROVALS: WEIGHING UP THE SOYBEANSGMOs are an integral part of our daily lives and the EU benefits hugely from the trade of genetically modified (GM) crop commodities. Our clothes and bank notes are made with GM cotton, and each year, our farm animals eat an amount of GM soybeans roughly equivalent to the combined weight of all EU citizens, an incredible number of almost 34 million tonnes. Livestock farmers, and ultimately all of us, are paying unnecessarily high prices because the EU system for GM im-port authorisations has become dysfunctional. Without GMOs, Europe’s big livestock farming sector would collapse, forcing farmers out of business, replacing local production with more meat imports to Europe, and further increasing prices for consumers.

A HISTORY OF INSTITUTIONAL LAW BREAKINGThe lack of institutional respect for democratically

The State of Agricultural Biotech in Europe

Beat Späth, EuropaBio Director of Agricultural Biotechnology

Time to think again.

agreed EU laws and procedures was confirmed by Court and WTO rulings. The system for cul-tivation authorisations has never been correctly implemented, and several national bans were confirmed to be illegal. As a result, most arable crop farmers in the EU have always been denied the freedom to choose which safe products to grow. In March 2015, a legislation was adopted which enables Member States to ban their farm-ers even more easily from growing safe products approved at EU level. Apart from confirming Eu-rope’s direction towards becoming a museum of world farming, this sets a very bad precedent for the internal market and science-based deci-sion-making. Now we know that this was not an isolated initiative for cultivation only. Which safe products will be banned next?

ESCAPING THE POLITICS OF FEARI hope that 2015 will mark a shift towards co-herent policy-making. Many politicians seem to have given up to unfounded concerns. But voting against or otherwise blocking or delaying the au-thorisation of safe products will not change but only solidify these unfounded concerns, as will efforts to create policy-based facts rather than fact-based policies. The EU is in a vicious circle of a lack of approvals and decreased trust: no vote - no trust, no trust - no vote. This negative precedent of “politics over science” has a major and concrete impact on companies’ decisions where to invest (beyond the biotech field). Pub-lic researchers also face protests and illegal de-structions of field trials, and radical activists even invaded the European Food Safety Authority with smoke bombs. Let’s make sure that facts and freedom of choice prevail over scaremongering.

15

Re

view

of ye

ar past &

futu

re o

utlo

ok

The most obvious and easy generator of inno-vation, jobs and growth is to approve safe new products in reasonable timelines.

TIME TO THINK AGAINPublic perception is gradually improving, espe-cially where media reduce their pickup of un-founded scaremongering and where politicians dare tell the truth: genetic modification causes no harm whatsoever and is simply a targeted tool to improve plants, which have helped farm-ers grow more sustainably to feed the growing

world population. GMOs with direct consumer benefits (such as plants producing healthier oils) are currently entering the market. Where farm-ers are given the choice, millions decide to buy and grow biotech seeds. The number of farmers growing GM crops today is larger than all farmers in the EU, and they grow GMOs on an area larger than the entire EU arable land. Meanwhile the EU, with a cradle of GMO innovation in Ghent, Belgium, has turned from leader to laggard. Time to think again!

Beat Späth

16

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Achievements

17 GM products for import approved

In April 2015, the European Commission au-thorised imports of 17 GM products which had been pending on average 6.5 years from the time of submission until the final authorisation. There are now over 40 additional GM applica-tions for import waiting in the system. Europa-Bio has called on the Commission* to continue granting Europe’s livestock farmers freedom of choice by approving products in a timely and predictable fashion. EuropaBio also published regular updates on the status of ‘Undue De-lays’** of GMO import authorisations with the aim of highlighting what remains to be done.

* http://tinyurl.com/nekmbr9 ** http://tinyurl.com/o3asmcr

Europe à la carte?

In April 2015, the European Commission pre-sented a proposal to allow individual Member States to ban the use of imported GMOs on their territories on the basis of non-scientific criteria. EuropaBio organised the first high level event on the shocking proposal that was attended by over 100 representatives from EU institutions and Member States, the food and feed supply chain as well as NGOs and media, with a special keynote speech delivered by Arūnas Vinčiūnas, Head of Cabinet of Commissioner for Health and Food Safety. Participants discussed how the proposal could affect international trade and what it could mean for Europe’s internal market, as well as whether it sets a precedent for a ‘Europe à la carte’ that could spill over to other sectors. The conclusion by the food and feed chain actors and third countries was that they could not see how this proposal fits with the Commission’s jobs and growth and better and smart regulation agendas or how it can ac-tually be implemented. At the event EuropaBio also launched the video of the journey of Mr. Maize, a genetically modified maize from Brazil, to Europe.*

* http://tinyurl.com/nq5hs8j

Making a point about facts

In an effort to put the new proposal to allow Mem-ber States to ban the use of GMO imports into perspective, EuropaBio published facts about the quantity of GMOs imported into the EU* and used in individual Member States**, highlight-ing that even Member States that vote against GMO approvals, are heavily dependent on GMO trade. In addition, in order to familiarise stake-holders with the GMO authorisation process***, EuropaBio prepared an infographic explaining how the approval process for import of GMOs in the EU is currently working.

* http://tinyurl.com/ohbvokv** http://tinyurl.com/owkgnkn*** http://tinyurl.com/pgnkcty

17

Re

view

of ye

ar past &

futu

re o

utlo

ok

New study on benefits from IP rights for agricultural innovation

In November 2014, EuropaBio launched a new study* on actual benefits resulting from intellectual property rights applied in agricultural innovation. The study was conducted on the case of Ogura, an oilseed rape hybridisation technology developed by the French Public Research Institute INRA. The study showed that the fact that Ogura had been protected with the help of intellectual property allowed the creation of €1.2 billion in economic benefits to society — a significant boon for the French economy.

*http://tinyurl.com/m79mjay

What is said and thought of GMOs

Ever wondered what people say about GMO safety?* EuropaBio launched a new eye-opening factsheet on what European leaders and world-wide renowned institutions say about GMOs.

And what about us? How gene’ophobic are we? Recent polls show that a majority of EU citizens does not feel strongly about genetic engineering. Our infographic on public perception** picks up the latest data on the position of Europeans towards GMOs.

* http://tinyurl.com/oy4uayo

#TradeTalk

With the aim of getting a conversation going around the EU’s dependency on GMO imports, EuropaBio launched a blog section at the beginning of March 2015 called Trade Talk* dedicated to the news and views on GM crop imports from around Europe.

* http://growingvoices.eu/blog/tradetalk/

THE EUROPEAN COMMISSION“The main conclusion to be drawn from the efforts of more than 130 research projects, covering a period of more than 25 years of research, and involving more than 500 independent research groups, is that biotechnology, and in particular, GMOs, are no more risky than conventional plant breeding technologies.”

A Decade of EU-funded GMO Research (2001-2010), 2010

18

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

With the dust now settling after the arrival of the new Juncker Commission last September, pol-icy opportunities and challenges are becoming clearer for biobased industries. President Junck-er’s new approach, aimed at slicing through well-established policy silos holds promise for cross cutting issues, such as the development of a competitive and sustainable bioeconomy.

Although several important milestones were reached during Barosso II, including the launch of the 3.7 billion biobased industries public pri-vate partnership, leaders in this field continue calling for a more holistic, coherent, supportive and predictable approach towards bioeconomy policy making.

The benefits of EU biobased industries should resonate well enough among thought leaders within the new Commission for their potential to tackle climate change while reducing depen-dence on fossil-carbon imports, and creating jobs and growth. Now it’s time for the Juncker Commission to put the necessary measures in place to retain and attract greater investment in this sector.

Furthermore, the backlash to the Commission’s announcement of the withdrawal of the Circular Economy proposal and the subsequent show of support, from the European Parliament, to Mem-ber States, industry and NGOs, has highlighted the demand for more sustainable, renewable products and processes, including biobased. Biobased industries are united in their long term wish for the deployment of the demand-side stimulation measures, finalised by the Lead Mar-ket Initiative group on biobased products, and left

The State of Industrial Biotech in Europe

Joanna Dupont-Inglis, EuropaBio Director of Industrial Biotechnology

Policy into practice – en route towards Bioeconomy 2.0

only partially implemented after their publication in 2011. Experts in biobased are exploring the possibilities held by public procurement and are increasingly examining the fine detail on regula-tory and other barriers to establishing a dynamic internal market.

Access to competitively priced feedstock re-mains a concern with an ongoing need for ap-propriate rural development and regional funding programmes to help establish and support new value chains and partnerships. In this respect, championing agricultural productivity and sus-tainability will be key, as well as putting in place measures and schemes to support collection, storage and transportation of renewable raw ma-terials, especially agricultural residues.

Accessing combined funding for the construc-tion of new demonstration and flagship biore-fineries remains a critical issue to help bridge the innovation ‘valley of death’ and reverse the migration trend of Europe’s leading industrial bio-tech pioneers abroad to more supportive and enabling environments. Facilitating such access will be integral to attracting future private invest-ment and to overcoming the dependence on the fossil-based “business as usual” approach. As yet, however, industry remains baffled by the complexities, inconsistencies and overwhelming administrative labyrinth of combining regional, national, Horizon 2020 and EIB funding, amongst other budget lines. Simplifying and harmonising these funding rules and aligning basic funding principles will be fundamental to boosting green jobs, growth, markets and biobased industry con-fidence in Europe.

19

Re

view

of ye

ar past &

futu

re o

utlo

ok

President Juncker has set the scene for change through a bold move to transform the way in which his Commissioners will work together across policy sectors. Bold political moves are exactly what is needed to get the EU back on track and to deliver solutions to tackle the com-bined threats of climate change, energy and food security, while ensuring sustainable economic recovery.

Industrial biotech and biobased industries will play a critical role on the journey towards de-livering these objectives. But time is short and trans policy vision and action are needed to en-sure that the new Commission and the Member States help provide a ‘make’ rather than ‘break’ moment for Europe’s leading Industrial Biotech Sector.

Joanna Dupont-Inglis

20

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Achievements

European Joint Undertaking (JU) on Biobased Industries (BBI)

On 9 July 2014 EU and industry leaders launched a new European Joint Undertaking (JU) on Bio-based Industries (BBI). The aim was to trigger investments and create a competitive market for biobased products and materials sourced locally and “Made in Europe”, tackling some of the EU’s biggest societal challenges. The launch of the BBI JU was a milestone for EuropaBio whose board held the first meeting with the Barroso II Commission calling for a Joint Undertaking with the then Research and Innovation Com-missioner, Maire Goeghegan Quinn. EuropaBio subsequently played a formative role in the de-velopment and realisation of the initiative as pro-viders of cutting edge technology, adding value to numerous other leading European sectors.

http://bbi-europe.eu

Formation and launch of the European Bioeconomy Alliance

On 4 February 2015 in the European Parliament, EuropaBio and a group of other associations launched the European Bioeconomy Alliance. The Alliance seeks to help develop a world leading, dynamic and competitive bioeconomy, based on renewable raw materials in the EU. It pools the expertise and efforts of many actors throughout the value chain, including the EU’s farmers, foresters, starch, sugar, bioethanol and plant derived oil producers as well as many other biobased industries.

Furthermore, the alliance calls for the de-velopment of a holistic, coherent and har-monised framework across a range of policy fields including agriculture, forestry, marine, industrial, climate, environment, energy, re-search, innovation and regional development.

http://bioeconomyalliance.eu

Former EC President José Manuel Barroso and Commissioners Maire Goeghegan Quinn and Neelie Kroes at the launch of the European

Joint Undertaking (JU) on Biobased Industries (BBI)

21

Re

view

of ye

ar past &

futu

re o

utlo

ok

Record attendance at the biggest ever European IB event: the European Forum on Industrial Biotech and the Bioeconomy2014 (EFIB)

In 2014 EFIB offered unparalleled opportunities to showcase the benefits and breakthroughs in industrial biotech to a high level audience of business and policy decision makers and thought leaders. In 2014 EFIB brought together over 700 participants from 39 countries with around 50% of attendees of C, Board, Director, President of VP levels. 2015 will see EFIB retur-ning to Brussels, its place of origin with a special focus on the potential of Industrial Biotech to provide world leading, sustainable solutions to the challenges of developing a circular economy and mitigating the impacts of climate change.

http://www.efibforum.com

The BIO-TIC project – leveraging €2.8million for tackling challenges to industrial biotech

The BIO-TIC project aims to raise awareness and understanding of the benefits of industrial biotech, drive technological innovation and build solid foundations for this growing, high value sector in the EU. Over the past three years BIO-TIC has gathered information, insights and expertise from across Europe on the barriers and solutions to boosting uptake of this key enabling technology. Highlights of the past year include:

5 business case workshops attended by 157 participants held throughout Europe on biobased chemical building blocks, CO2 as a feedstock for white biotech, biopolymers, 2G ethanol and bio jetfuels and on biosurfactants.

A revamped website with (1) clear, straightfor-ward info on IB basics, its benefits and innovativeexamples of IB use; and (2) country profiles forwhat is going on in terms of IB in the Member States;

The BIO-TIC final conference took place at the Royal Flemish Academy for Sciences and Arts –KVAB on 23 June 2015 and was entitled ‘From bugs to business – Unlocking the Bioeconomy in Europe’. The conference saw the official launch of the BIO-TIC final roadmap containing a com-prehensive set of recommendations to boost the technology in Europe. It attracted over 120 participants from the fields of policy making, civil society, industry and academia and included an exhibition of biobased products enabled by IB. The conference also showcased the tools de-veloped during the project. The conference was followed by a visit of the Bio Base Europe Pilot Plant on the next morning.

www.industrialbiotech-europe.eu

EFIB 2014, where policy meets industry, was held in Reims, France

22

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

EuropaBio TeamNathalie MollSecretary General

@NathalieMoll

Catherine De FeyterSenior Manager, Finance, HR and Office Administration

@c_defeyter

Miriam GargesiDirector, Healthcare Biotechnology

@mgargesi

Violeta GeorgievaOfficer, Agricultural Biotechnology

@VioletaGeor

Delphine CarronRegulatory Affairs Manager, Agricultural Biotechnology

@DelphineCarron

Christine DevauxPA to the Secretary General, IT Manager

Joanna Dupont - InglisDirector, Industrial Biotechnology

@joannadupont

23

Re

view

of ye

ar past &

futu

re o

utlo

ok

Claire GrayProject Coordinator, Industrial Biotechnology

@bioscience_info

Katarzyna JasikCommunications Manager, Agricultural Biotechnology

@KasiaJasik

Riccardo MezzasalmaOfficer, Healthcare Biotechnology

@RiccardoMezzasa

Mélanie Moxhet Assistant, Administration and Communications

@MelaMox

Antoine PeetersManager, Industrial Biotechnology and EU Projects

@apeeters

Cosmin PopaManager, Communications and National Associations

@co5min_popa

Ioana PopescuOfficer, Industrial Biotechnology

@ipopescu1

Pedro Narro Sanchez Public Affairs Manager, Agricultural Biotechnology

@pedroraulnarro

Beat SpäthDirector, Agricultural Biotechnology

@BeatSpath

24

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

EuropaBio Members

Our membership includes a wide range of corporate members and industry associations involved in biotechnology throughout Europe. EuropaBio has 60 corporate and 13 associate members and BIO Regions and 16 national biotechnology associations - representing some 1800 small and medium-sized enterprises across Europe.

Corporate Members

AbbVie

Alexion

Amgen

ARD

Areta International

Autifony Therapeutics

BASF

Baxter

Bayer

BBB Therapeutics BV

BioAmber

Biogen

Biomarin

BIO-ON srl

Biosyntia ApS

Clariant Produkte GmbH

Corbion Purac

CSL Behring

Dow AgroSciences

DSM

DuPont de Nemours

Eli Lilly

Erydel SPA

Erytech Pharma

E-Therapeutics

Evonik

Gensight Biologics

Genzyme

GlaxoSmithKline

Global Bioenergies SA

Intrexon Actobiotics NV

Keygene

Knowledge Transfer Network Ltd

KWS

Leitat Technology Center

Limagrain

MerckSerono

Monsanto

MSD Europe

Nanobiotix

NatureWorks

Novamont

Novartis

Novo Nordisk

Novozymes

Orphan Europe

Pfizer

Protaffin Biotech- nology AG

PsiOxus Therapeutics LTD

Raptor Pharmaceuti-cals Europe BV

Roquette Frères

Sanofi Pasteur MSD

Shire

Solvay

Swedish Orphan Biovitrum

Syngenta

Transgene

uniQure NV

Vitromics Healthcare Holding B.V

ZeClinics

25

Re

view

of ye

ar past &

futu

re o

utlo

ok

BIO.NRW Expert Services & Advice in Healthcare BVBA

Perseus

Cambridge Biomedical Consultants LTD

Industries et Agro-Resources SFL Services

Deerfield Management Company LP

IQX TNO

Dr Regenold Gmbh Nestlé Voisin Consulting

European Organisation for Research and Treatment of Cancer

Associate Members and BIO Regions

National Associations

Belgium | Bio.be Lithuania | Lithuanian Biotech Association

Denmark | Dansk Biotech The Netherlands | HollandBIO

Finland | FIB Norway | Norwegian Bioindustry Association

France | France Biotech Spain | ASEBIO

Germany | BIO Deutschland Sweden | SwedenBio

Germany | DIB Switzerland | Swiss Biotech Association

Ireland | IBIA Switzerland | scienceindustries

Italy | Assobiotec United Kingdom | BIA

26

Re

vie

w o

f ye

ar p

ast

& f

utu

re o

utl

oo

k

Design and graphic production: Oktan Stavanger – www.oktanstavanger.noPrinted by: Drukkerij Geers Offset

EuropaBio team photos by: Vivian Hertz – www.vivianhertz.be

View online version at: http://biotechaddress.europabio.org

27

Re

view

of ye

ar past &

futu

re o

utlo

ok

EuropaBioAvenue de l’Armée 6,1040 Brussels (Belgium)Tel +32 2 735 03 13Fax +32 2 735 49 60

Follow us on Twitter, Facebook and LinkedIn